NetWorth
LeaderPortfolio
Sahin
Ugur Sahin
Rank #1137
GERMANY•Healthcare•Biotechnology

Ugur Sahin

Net Worth
$3.709B
-0.38% (24h)
Ugur Sahin, born in 1965, is a German medical researcher, entrepreneur, and businessman, and is currently ranked #908 on the Forbes Billionaires list. As the co-founder and CEO of BioNTech, Sahin has significantly impacted the biotechnology industry. His wealth source is rooted in biotechnology, specifically in the development of mRNA-based immunotherapies and vaccines. Sahin's career began in medicine, with a doctorate in cancer immunotherapy, and he later pursued research and academic roles before entering the entrepreneurial world. His most notable achievement is co-developing the first mRNA-based vaccine for COVID-19, with BioNTech's partner Pfizer. He also leads research on cancer vaccines. Sahin's pioneering work has led to several breakthroughs, earning him recognition and awards in the scientific community.

How to read Ugur Sahin's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Ugur Sahin, we anchor the narrative to Biotechnology and Biotechnology, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.709B alongside global rank #1137, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (GERMANY) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Ugur Sahin was born on September 19, 1965, in İskenderun, Turkey. At the age of four, he moved to Germany with his family, where his father worked in a Ford factory. Sahin excelled academically, graduating from the Erich-Kästner-Gymnasium in Cologne-Niehl in 1984. He pursued his medical studies at the University of Cologne from 1984 to 1992. During this time, he completed a doctoral thesis on immunotherapy against tumor cells, earning a summa cum laude. From 1992 to 1994, he studied mathematics at the Fernuniversität Hagen.

Rise to Success

Sahin's career includes impactful roles in both academia and industry. After his residency, he worked as a physician in internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne and then at the Saarland University Hospital in Homburg. In 1999, he habilitated in molecular medicine and immunology. In 2000, he joined the University Medical Center Mainz. Sahin co-founded Ganymed Pharmaceuticals in 2001 and later BioNTech in 2008 with his wife, Özlem Türeci, and Christoph Huber. BioNTech's collaboration with Pfizer to develop the COVID-19 vaccine was a pivotal moment, transforming the company and propelling Sahin into the global spotlight.

Key Business Strategies

Key business strategies include focusing on mRNA technology for cancer and infectious diseases. BioNTech's success is linked to its ability to translate scientific discoveries into life-saving treatments.

Philanthropy

Specific philanthropy amounts for Ugur Sahin could not be found; however, his charitable ethos has kept him grounded.

Career Timeline

2020

Developed COVID-19 Vaccine

Co-developed the first mRNA-based vaccine against COVID-19 in partnership with Pfizer.

2008

Co-founded BioNTech

Co-founded with Özlem Türeci and Christoph Huber, focused on immunotherapies and vaccines.

2001

Co-founded Ganymed Pharmaceuticals

Founded with Özlem Türeci and Christoph Huber, focused on cancer treatments. Sold in 2016.

Philanthropic Impact

Not AvailableUndisclosed

Not Available

No specific information about his philanthropy could be found.

Key Business Ventures & Holdings

CompanyStakeValue
BioNTech42.37%$11.6M

Net Worth History

In-Depth Analysis

Early Life and Education

Ugur Sahin was born on September 19, 1965, in İskenderun, Turkey. At the age of four, he moved to Germany with his family, where his father worked in a Ford factory. Sahin excelled academically, graduating from the Erich-Kästner-Gymnasium in Cologne-Niehl in 1984. He pursued his medical studies at the University of Cologne from 1984 to 1992. During this time, he completed a doctoral thesis on immunotherapy against tumor cells, earning a summa cum laude. From 1992 to 1994, he studied mathematics at the Fernuniversität Hagen.

Rise to Success

Sahin's career includes impactful roles in both academia and industry. After his residency, he worked as a physician in internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne and then at the Saarland University Hospital in Homburg. In 1999, he habilitated in molecular medicine and immunology. In 2000, he joined the University Medical Center Mainz. Sahin co-founded Ganymed Pharmaceuticals in 2001 and later BioNTech in 2008 with his wife, Özlem Türeci, and Christoph Huber. BioNTech's collaboration with Pfizer to develop the COVID-19 vaccine was a pivotal moment, transforming the company and propelling Sahin into the global spotlight.

Key Business Strategies

Key business strategies include focusing on mRNA technology for cancer and infectious diseases. BioNTech's success is linked to its ability to translate scientific discoveries into life-saving treatments.

Philanthropy

Specific philanthropy amounts for Ugur Sahin could not be found; however, his charitable ethos has kept him grounded.

Data Sources & Methodology

Figures for Ugur Sahin are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom